Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1080 pg versus Oral transmucosal fentanyl citrate 1600 pg and dose proportionality of FEBT 270 to 1300 μg: A single-dose, randomized, open-label, three-period study in healthy adult volunteers

Clinical Therapeutics

Volumn 28, Issue 5, 2006, Pages 715-724

  Darwish, Mona ^a   Tempero, Kenneth ^b   Kirby, Mary ^a   Thompson, Jeffrey ^b  

^a CEPHALON INC   (United States)

^b CIMA Labs Inc Minnesota   (United States)

Author keywords

effervescence; fentanyl; fentanyl effervescent buccal tablet; oral transmucosal fentanyl citrate; pharmacokinetics

Indexed keywords

FENTANYL; FENTANYL CITRATE; NALTREXONE;

ADULT; APPLICATION SITE ERYTHEMA; APPLICATION SITE REACTION; AREA UNDER THE CURVE; ARTICLE; CHEEK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; HUMAN; HYPOTENSION; LABORATORY TEST; LOZENGE; MALE; MOLAR TOOTH; MOUTH DISCOMFORT; MOUTH MUCOSA; NAUSEA; NORMAL HUMAN; PHYSICAL EXAMINATION; PULSE OXIMETRY; RANDOMIZED CONTROLLED TRIAL; STOMACH DISCOMFORT; VENOUS BLOOD; VITAL SIGN;

ADMINISTRATION, BUCCAL; ADMINISTRATION, ORAL; ADULT; ALGORITHMS; ANALGESICS, OPIOID; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; NEBRASKA; PAIN; TIME FACTORS;

EID: 33746849278     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.05.016     Document Type: Article

References (14)

1. Stanley T.H. Fentanyl. J Pain Symptom Manage 29 Suppl 5 (2005) S67-S71
2. Bennett D., Burton A.W., Fishman S., et al. Consensus panel recommendations for the assessment and management of breakthrough pain: Part 2 management. Pharm Ther 30 (2005) 354-361
3. Pather S.I., Siebert J.M., Hontz J., et al. Enhanced buccal delivery of fentanyl using the OraVescent drug delivery system. Drug Deliv Tech 1 (2001) 54-57
4. Durfee S., Messina J., and Khankari R.K. Fentanyl effervescent buccal tablets: Enhanced buccal absorption. Am J Drug Deliv 4 (2006) 1-5
5. Eichman J.D., and Robinson J.R. Mechanistic studies on effervescent-induced permeability enhancement. Pharm Res 15 (1998) 925-930
6. Eichman J.D., Yassin A.E.-D.B., and Robinson J.R. The influence of in-vivo carbonation on GI physiological processes and drug permeability. Eurj Pharm Biopharm 44 (1997) 33-38
7. Fine P.G., Marcus M., De Boer A.J., and Van der Oord B. An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain. Pain 45 (1991) 149-153
8. Darwish M., Tempero K., Kirby M., and Thompson J. Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet 44 (2005) 1279-1286
9. [EMEA Web site]. ICH Topic E6. European Agency for the Evaluation of Medicinal Products. Accessed April 13, 2006. International Conference on Harmonisation-World Health Organization. Guideline for Good Clinical Practice (2002), WHO, Geneva, Switzerland. http://www.emea.eu.int Accessed April 13, 2006
10. 1983 Metropolitan height and weight tables. Stat Bull Metrop Life Found 64 (1983) 3-9
11. Actiq (oral transmucosal fentanyl citrate 400 μg) [product information] (2004), Cephalon, Inc, Frazer, Pa
12. Available at:. US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. Accessed April 26 (2005). http://www.fda.gov/cder/guidance/3616fnl.pdf
13. Smith B.P., Vandenhende F.R., DeSante K.A., et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res 17 (2000) 1278-1283
14. Available at:. US Food and Drug Administration (FDA). Catalog of FDA Approved Drug Products: Actiq (NDA) #020747 Drug Details. Drug Details. Accessed February 9 (2006). http://www.accessdata.fda.gov/scripts/cder/dmgsatfda/index.cfm?fuseactio n=Search